{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:42Z","timestamp":1793928942320,"version":"4.8.0"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105037","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:12:15Z","timestamp":1763701935000},"page":"105037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-547X","authenticated-orcid":false,"given":"Onyekachi J.","family":"Okpasuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olamide T.","family":"Olaoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bokolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloysius S.","family":"Aleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayobami","family":"Dare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope I.","family":"Adelusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa D.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105037_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/PHMT.S429252","article-title":"Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma","volume":"14","author":"Abdur Raqib","year":"2023","journal-title":"Pediatr. Health Med Ther."},{"key":"10.1016\/j.critrevonc.2025.105037_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97805","article-title":"TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies","volume":"3","author":"Ahmed","year":"2018","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105037_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105037_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112516","article-title":"The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer","volume":"146","author":"Alemohammad","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib6","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.105037_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838133","article-title":"Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches","volume":"13","author":"Ayoub","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102943","article-title":"Antibody-Drug Conjugates-A Tutorial Review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105037_bib9","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105037_bib10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: Mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105037_bib12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105037_bib14","series-title":"Radiotheranostics - a primer for medical physicists I: Physics, chemistry, biology and clinical applications","year":"2024"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105037_bib15","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00277-016-2731-x","article-title":"Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma\/leukemia","volume":"95","author":"Burkhardt","year":"2016","journal-title":"Ann. Hematol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105037_bib17","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105037_bib18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105037_bib19","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","article-title":"Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody\u2013Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non\u2013Small Cell Lung Carcinoma","volume":"27","author":"Camidge","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","article-title":"Cancer-associated fibroblasts as therapeutic targets for cancer: Advances, challenges, and future prospects","volume":"32","author":"Cao","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/ijms21041388","article-title":"Role of VEGFs\/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models","volume":"21","author":"Ceci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib22","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib23","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab","volume":"9","author":"Chin","year":"2018","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib24","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: A phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105037_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 Signaling in Cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"issue":"6165","key":"10.1016\/j.critrevonc.2025.105037_bib29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Cancer Immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.critrevonc.2025.105037_bib30","doi-asserted-by":"crossref","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","article-title":"A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1","volume":"292","author":"De Nardis","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.105037_bib31","series-title":"Pharmaceutical Biotechnology","first-page":"165","article-title":"Monoclonal Antibodies: From Structure to Therapeutic Application","author":"Deng","year":"2024"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib32","article-title":"Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105037_bib33","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab Pasudotox: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115213","article-title":"Development of T-cell engagers selective for cells co-expressing two antigens","volume":"14","author":"Dicara","year":"2022","journal-title":"MAbs"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105037_bib35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/cbr.1997.12.223","article-title":"Magic Bullets at Last! Finally\u2014Approval of a Monoclonal Antibody for the Treatment of Cancer!!!","volume":"12","author":"Dillman","year":"1997","journal-title":"Cancer Biotherapy Radiopharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105037_bib37","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","article-title":"Design and Efficacy of a Monovalent Bispecific PD-1\/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells","volume":"11","author":"Dovedi","year":"2021","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific Antibodies in the Treatment of Hematologic Malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105037_bib39","doi-asserted-by":"crossref","first-page":"S647","DOI":"10.1016\/j.annonc.2023.09.2214","article-title":"1075TiP A phase I\/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed\/refractory HER2-expressing solid tumors","volume":"34","author":"Dumbrava","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105037_bib40","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2023-189088","article-title":"The CD38\/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas","volume":"142","author":"Dupuy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105037_bib41","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"ement_1","key":"10.1016\/j.critrevonc.2025.105037_bib42","article-title":"AFM24 in combination with autologous NK cells (SNK01) in patients with advanced\/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study","volume":"9","author":"El-Khoueiry","year":"2023","journal-title":"JCO Glob. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105037_bib43","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105037_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103447","article-title":"Next generation Fc scaffold for multispecific antibodies","volume":"24","author":"Estes","year":"2021","journal-title":"iScience"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/1568009618666180102102311","article-title":"Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update","volume":"18","author":"Eyvazi","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105037_bib46","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-22-0346","article-title":"SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGF\u03b2, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105037_bib47","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.3390\/ijms23137238","article-title":"Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and\/or the Cell Nucleus","volume":"23","author":"Fernandes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib48","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3390\/cimb46040190","article-title":"PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview","volume":"46","author":"Filippi","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.critrevonc.2025.105037_bib49","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2020.11","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","author":"Fujiwara","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.critrevonc.2025.105037_bib50","series-title":"Therapeutic Antibody Engineering","first-page":"57","author":"Fundamental technologies for antibody engineering","year":"2012"},{"key":"10.1016\/j.critrevonc.2025.105037_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther. Adv. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105037_bib53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/2326-6066.CIR-19-0798","article-title":"CD137\/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement","volume":"8","author":"Gaspar","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib54","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-020-16838-w","article-title":"Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody","volume":"11","author":"Geiger","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.105037_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105037_bib56","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.3390\/cancers14163906","article-title":"Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy","volume":"14","author":"Glabman","year":"2022","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105037_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168947","article-title":"The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105037_bib58","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-Human Study of Utomilumab, a 4-1BB\/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105037_bib59","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.18632\/oncotarget.27936","article-title":"Targeting cancer associated fibroblasts to enhance immunotherapy: Emerging strategies and future perspectives","volume":"12","author":"Hanley","year":"2021","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105037_bib61","first-page":"585","article-title":"A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer","volume":"57","author":"Heitz","year":"2023","journal-title":"Ann. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab Soravtansine: First Approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib63","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105037_bib64","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","article-title":"Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB\/HER2 Bispecific Antibody-Anticalin Fusion PRS-343","volume":"25","author":"Hinner","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000069863","article-title":"Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.critrevonc.2025.105037_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: A first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.critrevonc.2025.105037_bib67","doi-asserted-by":"crossref","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","article-title":"460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers","volume":"33","author":"Jhaveri","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105037_bib69","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-5284","article-title":"Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression","author":"Knuehl","year":"2022","journal-title":"Cancer Res."},{"issue":"5517","key":"10.1016\/j.critrevonc.2025.105037_bib70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib71","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab Tesirine: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib73","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2189974","article-title":"Structure-based engineering of a novel CD3\u03b5-targeting antibody for reduced polyreactivity","volume":"15","author":"Liu","year":"2023","journal-title":"MAbs"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105037_bib74","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: A phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105037_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1012841","article-title":"Nanobodies in cell-mediated immunotherapy: On the road to fight cancer","volume":"14","author":"Maali","year":"2023","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105037_bib76","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105037_bib77","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105037_bib79","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib80","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.ijrobp.2011.12.070","article-title":"Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406","volume":"83","author":"Michalski","year":"2012","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGF\u03b2) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib82","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib83","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/cncr.34810","article-title":"FDA grants accelerated approval of mosunetuzumab for relapsed, refractory follicular lymphoma","volume":"129","author":"Nierengarten","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib84","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch. Biochem. Biophys."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.105037_bib85","article-title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib86","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.105037_bib87","article-title":"Phase 1 safety and efficacy of IMC-F106C, a PRAME \u00d7 CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"42","author":"Hamid","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib88","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab Plus Relatlimab: First Approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.105037_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114491","article-title":"New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies","volume":"161","author":"Pandey","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib90","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.105037_bib91","article-title":"Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study","volume":"42","author":"Pant","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105037_bib92","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105037_bib93","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105037_bib94","series-title":"Monoclonal antibody and peptide-targeted radiotherapy of cancer","year":"2010"},{"key":"10.1016\/j.critrevonc.2025.105037_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharm."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105037_bib96","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105037_bib97","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105037_bib98","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib99","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105037_bib100","first-page":"OF1","article-title":"FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","author":"Royce","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib102","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005147","article-title":"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors","volume":"10","author":"Sanborn","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib105","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105037_bib106","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov."},{"issue":"5416","key":"10.1016\/j.critrevonc.2025.105037_bib107","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/244444a0","article-title":"Human \u00d7 Mouse Somatic Cell Hybrid Clone secreting Immunoglobulins of both Parental Types","volume":"244","author":"Schwaber","year":"1973","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105037_bib108","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s Magic Bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib109","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105037_bib110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy","volume":"36","author":"Seimetz","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.105037_bib111","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) \u00d7 c-MET Antibodies and Antibody-Drug Conjugates","volume":"291","author":"Sellmann","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7900","key":"10.1016\/j.critrevonc.2025.105037_bib112","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib113","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105037_bib114","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib115","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/14796694.3.3.255","article-title":"Iodine 131 Tositumomab In the Treatment of Non-Hodgkin\u2018s Lymphoma","volume":"3","author":"Smith","year":"2007","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib117","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-19-2244","article-title":"Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1\/PD-L1 Inhibition in Merkel Cell Carcinoma","volume":"26","author":"Spassova","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105037_bib118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105037_bib119","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib120","first-page":"132","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib121","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: Target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib122","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105037_bib123","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib124","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab Govitecan: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105037_bib125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105037_bib126","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review","volume":"4","author":"Targeted Alpha Therapy Working Group","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib127","article-title":"The Role of Bispecific Antibodies in Non-Hodgkin\u2019s Lymphoma: From Structure to Prospective Clinical Use","volume":"11","author":"Tavarozzi","year":"2022","journal-title":"Antibodies (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105037_bib128","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105037_bib129","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","article-title":"Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB\/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors","volume":"23","author":"Tolcher","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers14020297","article-title":"Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development","volume":"14","author":"Tolmachev","year":"2022","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105037_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195847","article-title":"An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib132","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"MAbs"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib133","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jlcr.3622","article-title":"Aligning physics and physiology: E ngineering antibodies for radionuclide delivery","volume":"61","author":"Tsai","year":"2018","journal-title":"J. Label. Compd. Radiopharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib134","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"49","key":"10.1016\/j.critrevonc.2025.105037_bib135","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0029-1207589","volume":"16","author":"Ueber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren","year":"1890","journal-title":"DMW Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.critrevonc.2025.105037_bib136","series-title":"In S. Vallabhajosula, Molecular Imaging and Targeted Therapy","first-page":"533","article-title":"Radiolabeled Antibodies for Imaging and Targeted Therapy","author":"Vallabhajosula","year":"2023"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105037_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092659","article-title":"NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo","volume":"12","author":"Vallera","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105037_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13163994","article-title":"A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer","volume":"13","author":"Vallera","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib139","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"van de Donk","year":"2012","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105037_bib140","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc Enhanced EGFR\/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte\/Macrophage Trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2025.105037_bib141","article-title":"Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"83","author":"Wan","year":"2023","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105037_bib142","first-page":"90","article-title":"An optimal antitumor response by a novel CEA\/CD3 bispecific antibody for colorectal cancers","volume":"4","author":"Wang","year":"2021","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib143","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib144","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105037_bib145","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2123299","article-title":"Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names","volume":"14","author":"Wilkinson","year":"2022","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105037_bib146","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib147","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/acs.bioconjchem.1c00572","article-title":"Impact of drug conjugation on thermal and metabolic stabilities of aglycosylated and n-glycosylated antibodies","volume":"33","author":"Yamazoe","year":"2022","journal-title":"Bioconjug Chem."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.105037_bib148","article-title":"Preliminary dose escalation results from a first-in-human, phase I\/II study of GB263T, a novel EGFR\/cMET\/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)","volume":"41","author":"Yang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105037_bib149","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/imm.13636","article-title":"Trispecific antibodies for cancer immunotherapy","volume":"169","author":"Yao","year":"2023","journal-title":"Immunology"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105037_bib150","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/1078-0432.CCR-21-4256","article-title":"First-in-Human Phase I\/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response","volume":"28","author":"Yap","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105037_bib151","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/ijms21124309","article-title":"Current Perspectives on 89Zr-PET Imaging","volume":"21","author":"Yoon","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105037_bib152","article-title":"Bispecific antibodies: a smart arsenal for cancer immunotherapies","volume":"9","author":"You","year":"2021","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105037_bib153","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105037_bib154","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal Antibodies in Cancer Therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2025.105037_bib155","article-title":"Natural Killer Cell Engagers (NKCEs): A new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"46","key":"10.1016\/j.critrevonc.2025.105037_bib156","doi-asserted-by":"crossref","first-page":"e10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105037_bib157","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105037_bib158","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105037_bib159","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2024-207026","article-title":"Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 eradicate antigen-heterogeneous multiple myeloma, address antigen escape and enhance expansion","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:50:19Z","timestamp":1768333819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":159,"alternative-id":["S1040842825004251"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105037","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105037"}}